Cargando…

Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis

BACKGROUND: Cisplatin-based treatment has been considered the standard treatment regimen of HNSCC. Cetuximab is an emerging target therapy that has potential therapeutic benefits over cisplatin. Nevertheless, curative effects of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jingwen, Zhang, Jing, Shi, Changle, Liu, Lei, Wei, Yuquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002133/ https://www.ncbi.nlm.nih.gov/pubmed/27565887 http://dx.doi.org/10.1186/s12885-016-2706-2

Ejemplares similares

Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC
por: Ingruber, Julia, et al.
Publicado: (2022)

Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol
por: Ritter, M., et al.
Publicado: (2016)

Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis
por: Liang, Zhong Guo, et al.
Publicado: (2018)

Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis
por: Wang, Lin, et al.
Publicado: (2022)

Retracted: Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case–control study
por: Wu, Xin, et al.
Publicado: (2016)

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
por: O’Keefe, Rachel A., et al.
Publicado: (2020)

Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp
por: Wollina, Uwe, et al.
Publicado: (2011)

Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma
por: Tao, Chang-Juan, et al.
Publicado: (2014)

Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin
por: Crosby, James, et al.
Publicado: (2022)

Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report
por: Azad, Arun
Publicado: (2009)

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
por: Tang, Wen-Hua, et al.
Publicado: (2020)

A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck
por: Venkateshulu, Shruthi, et al.
Publicado: (2021)

Incidence and survival of HNSCC patients living with HIV compared with HIV-negative HNSCC patients
por: Haase, Katharina, et al.
Publicado: (2021)

Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series
por: Naruse, Tomofumi, et al.
Publicado: (2022)

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
por: Tu, Lingli, et al.
Publicado: (2013)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
por: Hecht, Markus, et al.
Publicado: (2021)

Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma
por: Bergstrom, Jennifer, et al.
Publicado: (2015)

Evaluation of a nurse-led aftercare intervention for patients with head and neck cancer treated with radiotherapy and cisplatin or cetuximab
por: Braat, Cora, et al.
Publicado: (2022)

Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Rassamegevanon, Treewut, et al.
Publicado: (2021)

Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hsieh, Meng-Che, et al.
Publicado: (2021)

Planned neck dissection following chemo-radiotherapy in advanced HNSCC
por: Gupta, Tejpal, et al.
Publicado: (2004)

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
por: Yao, Yanli, et al.
Publicado: (2022)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study
por: Brunner, Teresa F., et al.
Publicado: (2022)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial
por: Jones, David A., et al.
Publicado: (2020)

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
por: Klöss, Stephan, et al.
Publicado: (2015)

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
por: Sommariva, Michele, et al.
Publicado: (2013)

Correction: Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in‑vitro study
por: Brunner, Teresa F., et al.
Publicado: (2023)

A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
por: Li, H. M., et al.
Publicado: (2016)

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
por: Jeong, Il Seok Daniel, et al.
Publicado: (2020)

The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy
por: Huiskamp, L. F. J., et al.
Publicado: (2020)

First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
por: Falco, Agustín, et al.
Publicado: (2022)

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
por: Citron, Francesca, et al.
Publicado: (2021)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r8oj5p3bfcqhc3e6rvfrepcqve